Implementation of Biopharma SHAKTI

1. At a Glance

Biopharma SHAKTI = Strategy for Healthcare Advancement through Knowledge, Technology and Innovation — a Central Sector Scheme of the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers with a ₹10,000 crore outlay over 5 years to build a globally competitive ecosystem for biologics and biosimilars [S1][S2][S3].
Aims to shift India from a generics powerhouse to a global biologics/biosimilars manufacturing & innovation hub, with affordable healthcare focus on NCDs (cancer, diabetes, autoimmune) [S2][S4].
Relevant to UPSC for GS-III (Science & Tech, Economy, Health) and GS-II (Govt schemes, health policy).

2. Why in the News

Announced in Union Budget 2026–27 (Feb 2026) by FM and championed by Dr. Jitendra Singh as a catalyst for India's role in the next industrial revolution / biomanufacturing hub [S5][S6].
20 March 2026 — MoS Chemicals & Fertilizers Smt. Anupriya Patel in a written reply to Lok Sabha confirmed the ₹10,000 cr / 5-year outlay and scheme objectives [S1].
PIB Budget Series highlighted ₹13,000 crore combined provision for BioPharma SHAKTI + 3 dedicated chemical parks [S7].

3. Background & Evolution

Builds on India's "Pharmacy of the World" generics leadership; addresses gap in biologics/biosimilars where global revenue concentration is high but Indian share is low [S2][S4].
Predecessor / parallel initiatives: PLI Scheme for Pharmaceuticals & Bulk Drugs/APIs, Bulk Drug Parks Scheme, NIPERs network, BIRAC-DBT biotech support [S8].
Conceptually announced as part of Union Budget 2026–27; implementation framework released by DoP during FY 2026–27 [S5][S6].

4. Core Static Facts

Full form: Strategy for Healthcare Advancement through Knowledge, Technology and Innovation (SHAKTI) [S4].
Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals [S1].
Outlay: ₹10,000 crore over 5 years (from FY 2026–27) [S1][S2].
Targeted segments: Biologics, biosimilars, fermentation-based bulk drugs & building blocks [S3].
Major Components:
Biopharma Discovery Grant Fund + Discovery & Development Equity Fund [S3].
Biopharma-focused NIPER Network + National Biopharma R&D Network [S3].
India Clinical Trial Sites Network — 1,000 accredited sites under ICMR [S3][S4].
Fermentation-based Bulk Drugs & Building Blocks Manufacturing Incentive [S3].
3 new NIPERs + upgradation of 7 existing NIPERs [S3][S4].
Strengthening of CDSCO via dedicated scientific review cadre to meet global approval timelines [S3][S4].
Disease focus: Cancer, diabetes, autoimmune disorders (NCDs) [S2].
Innovation push: Adoption of Non-Animal Methodologies (NAMs) — organoids, organ-on-a-chip [S2].

5. Multi-Dimensional Analysis

Economic - Targets the high-value biologics market dominated by US/EU; biologics are projected to be ~35% of global pharma revenue, where India's share is marginal [S2]. - Combined with 3 dedicated chemical parks, total provision is ₹13,000 crore — flagged as a "strategic bet on India's future" [S7]. - Catalyses MSME/SME participation in advanced biomanufacturing via grant + equity funds [S3].

Scientific / Technological - Creates a National Biopharma R&D Network anchored on revamped NIPER ecosystem (existing 7 + 3 new) [S3][S4]. - Promotes fermentation-based bulk drug manufacturing, reducing API import dependence (esp. from China) [S3]. - Encourages NAMs (organoids, organ-on-a-chip) — aligns with global shift away from animal testing (US FDA Modernization Act 2.0) [S2].

Health / Social - Targets affordable access to biologics for NCDs — currently priced out of reach for many Indians [S2]. - Strengthens CDSCO regulatory capacity for faster, globally-acceptable approvals [S3].

Administrative - Convergence of multiple Ministries — DoP (nodal), DBT/BIRAC, ICMR (Health), CDSCO — risks coordination friction [S1][S3]. - Includes 1,000-site clinical trial network — significant federal-state coordination requirement [S3].

Strategic - Reduces strategic vulnerability in advanced therapies; complements Atmanirbhar Bharat in pharma [S4]. - Positions India as a global biomanufacturing hub in the "next industrial revolution" framing [S5].

6. Recent Developments (last 12-18 months)

Feb 2026: Scheme proposed in Union Budget 2026–27 as Biopharma SHAKTI [S5][S6].
Feb 2026: PIB Budget series — "Transforming India into a Global Biopharma Hub" document released [S4].
Feb–Mar 2026: Ministerial briefings flag ₹13,000 cr combined biopharma + chemical parks push [S7].
20 Mar 2026: Lok Sabha written reply by MoS Anupriya Patel formally confirms scheme structure [S1].
Parallel: Extension of PLI Scheme to APIs notified by DoP [S8].

7. Prelims Hooks

Biopharma SHAKTI stands for Strategy for Healthcare Advancement through Knowledge, Technology and Innovation [S4].
Outlay: ₹10,000 crore over 5 years [S1].
Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals (not Ministry of Health, not DBT) [S1].
Announced in Union Budget 2026–27 [S5].
Targets biologics and biosimilars (not generics) [S1].
Plans network of 1,000 accredited clinical trial sites under ICMR [S3].
Includes 3 new NIPERs + upgrade of 7 existing NIPERs [S3].
Regulator strengthened: Central Drugs Standard Control Organisation (CDSCO) [S3].
Promotes Non-Animal Methodologies (NAMs) — organoids, organ-on-a-chip [S2].
Includes Fermentation-based Bulk Drugs & Building Blocks Manufacturing Incentive [S3].
Two funds: Biopharma Discovery Grant Fund + Discovery & Development Equity Fund [S3].
MoS Chemicals & Fertilizers (replying in Lok Sabha 20 Mar 2026): Smt. Anupriya Patel [S1].
Combined provision with 3 dedicated chemical parks = ₹13,000 crore [S7].

8. Mains Relevance

GS-III — Science & Technology developments and their applications; Indian Economy — industrial growth; Health-sector reforms.
GS-II — Government policies and interventions for development in the health sector.
Probable question stems: 1. "Biopharma SHAKTI marks India's transition from a generics powerhouse to a biologics hub." Critically examine the scheme's design and likely bottlenecks. (GS-III) 2. Discuss how Biopharma SHAKTI complements existing PLI and Bulk Drug Park schemes in reducing India's API import dependence. (GS-III) 3. Affordable access to biologics for non-communicable diseases is a public health imperative. Evaluate Biopharma SHAKTI in this context. (GS-II)

9. Related Topics to Study Next

PLI Scheme for Pharmaceuticals & APIs — direct manufacturing-side complement [S8].
Bulk Drug Parks Scheme — infrastructure leg of pharma self-reliance.
NIPERs (National Institutes of Pharmaceutical Education & Research) — institutional vehicle of the scheme [S3].
CDSCO & Drugs and Cosmetics Act, 1940 — regulatory backbone for biologics approvals [S3].
BIRAC / Biotechnology Industry Research Assistance Council & DBT — biotech innovation funding ecosystem.
ICMR's clinical trial regulation & New Drugs and Clinical Trials Rules, 2019 — for 1,000-site network [S3].
Non-Communicable Diseases (NCDs) & National Programme for Prevention and Control of NCDs — demand-side rationale [S2].
Global biosimilars market & TRIPS flexibilities (WTO) — IP dimension.

10. Common Errors / Trap Areas

Wrong Ministry: It is DoP under Chemicals & Fertilizers, NOT Ministry of Health & Family Welfare or DBT [S1].
Outlay confusion: Scheme outlay is ₹10,000 cr; the ₹13,000 cr figure includes 3 dedicated chemical parks, not Biopharma SHAKTI alone [S1][S7].
Generics vs Biologics: Scheme targets biologics/biosimilars — easy to wrongly link to generic drugs / Jan Aushadhi [S2].
NIPER count: 3 new + 7 existing (total moves to 10), not "10 new" [S3].
Clinical trial sites under ICMR, not under CDSCO; CDSCO is strengthened separately for approvals [S3].
Budget year: Announced in Budget 2026–27, not 2025–26 [S5].

11. Sources

[S1] Implementation of Biopharma SHAKTI — Lok Sabha reply by MoS Anupriya Patel — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2242916 — (tier 1)
[S2] Biopharma SHAKTI Scheme (PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241168 — (tier 1)
[S3] Bio Pharma SHAKTI scheme (PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2237416 — (tier 1)
[S4] Transforming India into a Global Biopharma Hub — Budget 2026–27 Series (PIB) — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/feb/doc202622776701.pdf — (tier 1)
[S5] Budget 2026–27 announcement of Biopharma Shakti — Dr. Jitendra Singh (PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221778 — (tier 1)
[S6] Budget Push to Make India a Global Biopharma Hub (PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221492 — (tier 1)
[S7] ₹13,000 cr for BioPharma SHAKTI & 3 Dedicated Chemical Parks (PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2235160 — (tier 1)
[S8] Extension of PLI Scheme to API (PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2239580 — (tier 1)